SecBot SecBot
PRESS-RELEASE ·Filed Apr 13, 2026

PCRX

Pacira BioSciences
BULLISH
Impact 7/10
Horizonweeks Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The data strengthens EXPAREL's value proposition to payers and providers, potentially driving formulary adoption and reimbursement in outpatient orthopedic settings. Traders should monitor for increased commercial traction and potential pull-through in ZILRETTA and iovera° given shared commercial infrastructure.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$24.06
T+0 close · Apr 13, 2026 · via day close
Latest settled
+6.07%
T+60 · $25.52
Vs SPY
−2.85%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $24.06entry
  2. T+1 · 7mo ago −1.29%α −2.50% · $23.75
  3. T+5 · 7mo ago +3.49%α +0.20% · $24.90
  4. T+20 · 6mo ago −5.49%α −13.21% · $22.74
  5. T+60 · 4mo ago +6.07%α −2.85% · $25.52
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pacira BioSciences presented real-world data at AMCP 2026 showing EXPAREL® use in outpatient joint replacement surgeries is associated with lower total healthcare costs and reduced opioid utilization, particularly in patients with low back pain and in teaching hospitals. The findings reinforce EXPAREL's economic value and non-opioid pain management benefits.

Key Facts

  • EXPAREL use in THA was associated with lower total healthcare costs at 3 months ($7,332 vs $8,153) and 6 months ($13,022 vs $15,081) compared to non-LB.
  • In patients with low back pain, EXPAREL showed significantly lower costs at 6 months ($13,614 vs $18,652) and reduced opioid use by 51 MMEs at 6 months.
  • In TKA at teaching hospitals, EXPAREL was linked to statistically significant cost savings at surgical visit, 7 days, and 30 days post-op.
  • A 3-year budget model projected $117,868 in cumulative cost savings per 1 million members with EXPAREL vs ropivacaine.

Financial Impact

Projected cumulative cost savings of $117,868 per 1 million members over 3 years; per-member-per-month savings of $0.003

total healthcare costspharmacy costsopioid utilization

Risk Factors

  • Real-world studies show association, not causation, and may not translate into increased prescribing.
  • Forward-looking statements are subject to risks including regulatory, commercial execution, and clinical trial uncertainties.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3272431

Track record

29 reports on PCRX

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
  2. Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  3. Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
  5. Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
  6. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  7. Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  8. Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  9. Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
  10. Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026